Compare Gilead Sciences, Inc. (GILD) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nike Inc — how do they compare? Gilead Sciences, Inc. trades at $133.73 (market cap $163.51B), while Nike Inc trades at $44.17 (market cap $63.34B). The key difference: Gilead Sciences, Inc. is far larger — about 2.6× Nike Inc's market cap, and Nike Inc pays the higher dividend (3.83%). Which is the better fit depends on your goals.
| GILD | NKE | |
|---|---|---|
Market Cap | $163.51B | $63.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $79.24 |
52-Week Low | $108.22 | $40.75 |
Enterprise Value | $178.05B | $65.34B |
Dividend Yield | 2.49% | 3.83% |
Volume | — | 8,887,180 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Nike (NKE) trades at $42.86, down 2.06% today, with a bearish technical signal and recent earnings beats. Revenue declined to $46.31B in 2025, with net income margin at 6.7%. The stock shows strong profitability with ROE of 22.14% but faces headwinds in China and EMEA. Analysts maintain a consensus buy rating with a $50.80 price target, suggesting 18.5% upside.
Outlook remains cautious near-term due to sales pressure and margin compression, but long-term brand strength and digital DTC strategy offer recovery potential. Key risks include consumer demand softness and competitive pressures. The stock presents a contrarian opportunity if execution improves, supported by institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
